DYRK1A inhibitors for disease therapy: Current status and perspectives

T Liu, Y Wang, J Wang, C Ren, H Chen… - European journal of …, 2022 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a conserved
protein kinase that plays essential roles in various biological processes. It is located in the …

Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) in human disease, an overview

MF Lindberg, L Meijer - International Journal of Molecular Sciences, 2021 - mdpi.com
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and cdc2-
like kinases (CLK1-4) belong to the CMGC group of serine/threonine kinases. These protein …

GSK-3β, FYN, and DYRK1A: master regulators in neurodegenerative pathways

S Demuro, RMC Di Martino, JA Ortega… - International journal of …, 2021 - mdpi.com
Protein kinases (PKs) have been recognized as central nervous system (CNS)-disease-
relevant targets due to their master regulatory role in different signal transduction cascades …

Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases

MF Lindberg, E Deau, J Arfwedson… - Journal of medicinal …, 2023 - ACS Publications
Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases
(CLKs) play a large variety of cellular functions and are involved in several diseases …

The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities

J Boni, C Rubio-Perez, N López-Bigas, C Fillat… - Cancers, 2020 - mdpi.com
DYRK (dual-specificity tyrosine-regulated kinases) are an evolutionary conserved family of
protein kinases with members from yeast to humans. In humans, DYRKs are pleiotropic …

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics

DB Jarhad, KK Mashelkar, HR Kim… - Journal of medicinal …, 2018 - ACS Publications
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an
evolutionarily conserved family of protein kinases that belongs to the CMGC group of …

Selective DYRK1A inhibitor for the treatment of Type 1 Diabetes: Discovery of 6-azaindole derivative GNF2133

YA Liu, Q Jin, Y Zou, Q Ding, S Yan… - Journal of medicinal …, 2020 - ACS Publications
Autoimmune deficiency and destruction in either β-cell mass or function can cause
insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting β …

The omnipresence of DYRK1A in human diseases

E Deboever, A Fistrovich, C Hulme… - International journal of …, 2022 - mdpi.com
The increasing population will challenge healthcare, particularly because the worldwide
population has never been older. Therapeutic solutions to age-related disease will be …

DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome

A Feki, Y Hibaoui - Brain sciences, 2018 - mdpi.com
Down syndrome (DS) caused by a trisomy of chromosome 21 (HSA21), is the most common
genetic developmental disorder, with an incidence of 1 in 800 live births. Its phenotypic …

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

TL Nguyen, A Duchon… - Disease models & …, 2018 - journals.biologists.com
Growing evidence supports the implication of DYRK1A in the development of cognitive
deficits seen in Down syndrome (DS) and Alzheimer's disease (AD). We here demonstrate …